肺癌和卵巢癌患者血栓相关标志物的实验研究

Thrombosis-Related Markers in Patients with Pulmonary Cancer and Ovarian Cancer

目的观察肺癌和卵巢癌患者的血浆FⅧ活性(FⅧ:C)、FⅨ活性(FⅨ:C)、vWF抗原含量(vWF:Ag)、TpP含量变化与肺癌分期分型及卵巢癌的相关性。方法用凝固法在Stago全自动凝血仪上测定38例肺癌、11例卵巢癌患者、20名正常人FⅧ活性、FⅨ活性,用ELISA方法测定血浆vWF抗原含量、TpP含量。结果肺癌组和卵巢癌组血浆FⅧ:C,FⅨ:C,vWF:Ag、TpP含量均明显高于健康对照组,差异呈显著性(P<0.05)。肺癌Ⅲ～Ⅳ期与Ⅰ～Ⅱ期患者比较,血浆FⅧ:C、vWF、TpP含量明显升高,差异呈显著性(P<0.05),血浆FⅨ:C差异无显著性。鳞癌、腺癌、小细胞癌三组间FⅨ:C、FIX:C、TpP含量差异无显著性。鳞癌组vWF:Ag最高,与腺癌组差异呈显著性(P<0.05)。结论肺癌、卵巢癌患者处于血栓前状态,易发生血栓。FⅧ:C、vWF:Ag、TpP含量可作为对肺癌血栓前状态的诊断、判断预后及指导治疗的参考指标。

Objective To investigate the changes of FⅧ ： C and FⅨ ： C, vWF： Ag and TpP levels in patients with pulmonary cancer and ovrian cancer and their correlation with stage and type of lung cancer and ovrian cancer. Methods Plasma FⅧ：C and FⅨ：C were tested by solidification on the Stago Campct automatic coagulometer among 38 patients with pulmonary cancer , 11 patients with ovrian cancer and 20 healthy individuals. Plasma vWF： Ag and TpP levels were detected by enzyme -linked immunosorbent assay （ELISA）. Results Plasma FⅧ：c and FⅨ：C , vWF：Ag and TpP levels in patients with pulmonary cancer and ovrian cancer were significantly higher than healthy controls respectively （ P 〈 0.05 ） . Plasma FⅧ ： C, vWF：Ag and TpP levels in the Ⅲ - Ⅳstage patients with cancer was significantly higher than the Ⅰ - Ⅱ stage patients with pulmonary cancer respectively （P 〈 0. 05 ）. Plasma FⅨ ：C was not found significant differences between tow groups. Plasma F Ⅷ：C , FⅨ：C, TpP levels were not significantly different among patients with squamous - cell carcinoma, patients with adenocarcinoma and small cell lung cancer. Plasma vWF ： Ag was higher in patients with squamous - cell carcinoma than patients with adenocarcinoma respectively, （P 〈 0. 05 ）. Conclusions It suggested that patients with lung cancer and ovrian cancer were in prethrombotic state and they be proned to thrombosis. Plasma FⅧ：C, vWF：Ag and TpP levels could be as more sensitive indicators which was used to diagnose for prethrombotic state, evaluate progress of the condition, determine prognosis and recommend treatment for lung cancer.